US Patent Issued to JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG on Aug. 25 for "Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FCGammaR-independent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with FCGammaR-independent agonistic activity; TRAAFFIAA)" (German Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,715,928, issued on Aug. 25, was assigned to JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG (Wurzburg, Germany).

"Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FCGammaR-independent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with FCGammaR-independent agonistic activity; TRAAFFIAA)" was invented by Andreas Beilhack (Wurzburg, Germany), Juliane Medler (Fluda, Germany), Johannes Nelke (Wurzburg, Germany) and Harald Wajant (Kist, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to tumor necrosis factor (TNF) receptor superfamily (TNFRSF) rec...